3rd International Conference on CRISPR Technologies

From basic biology to versatile technologies: The CRISPR-Cas immune system and its applications in basic research, biotechnology, medicine, and agriculture
September 16-18, 2019
Add to Calendar

Presented by the Society for Biological Engineering (SBE), the CRISPR Tech 2019 conference will bring together academics and industry representatives to highlight the cutting edge of these developments and the most immediate technical and societal challenges.

Submit an abstract by May 17, 2019

Submit an Abstract

CRISPR Tech 2019 Flyer

CRISPR technologies represent versatile tools that have impacted sectors spanning from basic research and biotechnology to human health and agriculture. These technologies continue to develop at an astounding pace, with new advances and applications being reported on a seemingly daily basis. The CRISPR Tech 2019 conference will bring together academics and industry representatives to highlight the cutting edge of these developments and the most immediate technical and societal challenges. The conference will also discuss the basic features of CRISPR-Cas systems as defense mechanisms found in bacteria and archaea, and how new insights into these systems can give rise to the next generation of technologies. The conference venue will be in Würzburg, Germany, a picturesque German town centrally located in Europe and easily reached by train from Frankfurt and Munich international airports.

Keynote Speakers

Confirmed Invited Speakers

Conference Chairs

Session Topics

  • CRISPR-Cas Biology
  • Genome Editing and DNA Repair
  • Clinical and Biomedical Applications of CRISPR
  • Agricultural and Ecological Applications of CRISPR
  • Industrial Biotechnology Applications of CRISPR
  • Delivery and Specificity of CRISPR-based Tools
  • Social, Ethical, and Economic Implications of CRISPR

Organizing Committee

Featured Speakers

Jacob Corn

Jacob Corn is the Professor of Genome Biology at the ETH Zurich. His research aims to better understand and treat disease through next-generation genome editing technologies. Jacob’s career has bridged academia and industry, working in therapeutic areas that include infectious disease, neurobiology, and oncology. His research takes a multidisciplinary approach, combining cellular biochemistry, functional genomics, computational biology, bioengineering, and biophysics. In his spare time, Jacob enjoys long backpacking trips and rock climbing.Read more

Andrea Crisanti

Andrea Crisanti is professor of molecular parasitology at Imperial College, graduated in Medicine at the University of Rome "la Sapienza' and carried his doctoral work at the Basel Institute for Immunology. Prof. Crisanti has also been appointed full professor of Microbiology and Clinical Microbiology at the University of Perugia where until recently has coordinated the Centre of Functional Genomics. He has pioneered the molecular biology of the human malaria vector Anopheles gambiae and has made a number of important scientific contributions that advanced the genetic and molecular knowledge of the malaria parasite and its mosquito vector.Read more

Ashley Jacobi

Ashley Jacobi is a Senior Staff Scientist in the Molecular Genetics Research and Development group at IDT.  Ashley has been with IDT for 12 years and during that time she has published 18 manuscripts in peer-reviewed journals, contributed to numerous patent applications, and has presented at a wide variety of international biomedical research conferences.  She has been conducting research in RNAi and antisense oligo technologies, and more recently has been focusing on the development of novel CRISPR RNA sequences and modification patterns that allow for more efficient and...Read more

Yinan Kan

Yinan Kan is the Principle Scientist in the eGenesis gene editing team. He received his Ph.D. degree in 2015 in Biochemistry, Molecular Biology and Biophysics in the University of Minnesota with a research focus of dissecting the DNA repair pathways underlying homology-directed genome editing. He conducted postdoc research at Harvard Medical School before joining eGenesis Inc. He is devoted to developing novel technological platforms for multiplexed, precision and long-range genome editing with the aim of delivering safe and effective human transplantable organs from...Read more

Samira Kiani

Samira Kiani’s career is built around her passion for applying the CRISPR technology to synthetic biology. At Arizona State University, she has established her research program to combine CRISPR technology with Synthetic biology with an interest to develop safer and controllable gene therapies.Read more

Lina Leon

Lina M. Leon is a 4th year Ph.D. candidate in Dr. Joseph Bondy-Denomy’s group at UCSF and a recipient of the HHMI Gilliam Fellowship for Advanced Study. Prior to her graduate work, she completed a B.S. in chemistry at the University of Florida and was awarded an HHMI undergraduate research fellowship that she completed at UCSF.

Lina’s work primarily focuses on the biological underpinnings of Cas3-based CRISPR immunity and phage-encoded anti-CRISPR activity. She is eager to apply these lessons learned from bacteria and phage to develop and improve on genome engineering using Cas3....Read more

Randall Platt

Randy Platt studied biomedical engineering and chemistry at the University of Utah in Salt Lake City, Utah. In 2011 he obtained an MPhil from Imperial College London in material science and in 2015 a PhD from MIT in biological engineering. After a postdoctoral fellowship joint between MIT, Harvard University, and the Broad Institute he was appointed as a tenure-track assistant professor in the Department of Biosystems Science and Engineering (D-BSSE) at ETH Zurich and the Department of Chemistry at the University of Basel in October 2016.

...Read more

Tom Schreiber

During my PhD in the lab of Ulla Bonas (2010-2015, MLU Halle) I worked in the field of plant pathogen interactions, with particular interest in type 3 effector proteins of the transcription activator-like effector (TALE) family. TALEs allowed, for the first time, the design of artificial DNA-binding proteins with high specificity and a broad spectrum of applications including genome editing. After my PhD I moved to the field of synthetic biology in the lab of Alain Tissier (2015-now, IPB Halle). Here I expanded the repertoire of programmable tools for nucleic acid targeting (amiRNAs,...Read more

Gerald Schwank

Gerald Schwank started his group as an Assistant Professor of Stem Cell Biology & Disease Modeling in October 2014. He studied Genetics and Microbiology at the University of Vienna, and obtained his PhD in 2009 from the University of Zurich under the supervision of Prof. Konrad Basler. During his PhD he studied growth control in the Drosophila wing disc epithelium, and found that complementary gradients of growth factors drive uniform cell proliferation. After an additional two years at the University of Zurich as a postdoctoral fellow, he moved in 2011 to the Netherlands to the lab of...Read more

Virginijus Siksnys

Virginijus Siksnys studied chemistry at Vilnius University and obtained his Ph.D from Moscow State University before returning to Vilnius where he moved through different research ranks at the Institute of Applied Enzymology/Institute of Biotechnology. Since 2002 he holds the position of Professor of Vilnius University and serves as Chief scientist at the Institute of Biotechnology. Dr. Siksnys has made a major and sustained contribution to the understanding of the structure and function of restriction enzymes. His research on the CRISPR-Cas has had a major impact on the field. His studies...Read more

Thorsten Stafforst

Thorsten Stafforst started his independent lab in 2011 at the University of Tübingen, where he is now full professor for nucleic acid biochemistry. He studied Chemistry at the University of Göttingen, obtained his PhD in 2005 in Bioorganic Chemistry, and moved for a Postdoc with Prof. Don Hilvert at ETH Zurich. His research is focussed on the engineering of programmable RNA-targeted proteins. His lab has a particularly strong focus on therapeutic RNA editing by either engineering editases (gene therapy) or by designing antisense oligonucleotides that are tailored to harness endogenous...Read more

Mike Terns

CRISPR-Cas systems are recently discovered RNA-based adaptive immune systems that control invasions of viruses and other mobile genetic elements in prokaryotes (bacteria and archaea).

CRISPR-Cas systems function by capturing short invader sequences within the CRISPR locus of the host genome, producing short crRNAs from the CRISPR locus transcripts, and using the crRNAs to guide Cas protein-containing immune effector complexes to recognize and destroy the invading nucleic acids.

CRISPR-Cas based immunity is mediated by numerous and diverse Cas proteins and a given organism may...Read more